Pazorest 200 mg (Pazopanib)

Description

Pazorest 200 mg is a prescription anticancer medication whose active pharmaceutical ingredient is Pazopanib Hydrochloride. Pazopanib is a type of medication known as tyrosine kinase inhibitors (TKIs). Pazopanib is primarily prescribed to treat some particular kinds of cancer, particularly advanced renal cell carcinoma (RCC)—kidney cancer—and soft tissue sarcoma (STS) in adult patients with previous chemotherapy. Provided by various reputable pharmaceutical firms, Pazorest 200 mg is a targeted therapy to interfere with cancers by inhibiting certain enzymes essential in tumor growth and angiogenesis (angiogenesis being the generation of new blood vessels to nourish tumors).

Composition and Formulation

Pazorest 200 mg tablet consists of 200 milligrams of Pazopanib Hydrochloride or 200 mg of Pazopanib. The tablets have a generally film coating to allow for easy swallowing and to preserve the drug from moisture. The inactive ingredients may be microcrystalline cellulose, magnesium stearate, hypromellose, and other excipients that provide tablet stability and bioavailability.

Mechanism of Action

Pazopanib is a multi-targeted tyrosine kinase inhibitor. Pazorest inhibits the activity of a number of receptor tyrosine kinases (RTKs) that are involved in tumor cell proliferation and angiogenesis. Pazopanib selectively inhibits:

VEGFR-1, VEGFR-2, and VEGFR-3 (Vascular Endothelial Growth Factor Receptors)

PDGFR-α and PDGFR-β (Platelet-Derived Growth Factor Receptors)

FGFR (Fibroblast Growth Factor Receptors)

c-KIT, Lck, and c-Fms

By inhibiting these kinases, Pazopanib disrupts the signal transduction pathways leading to tumor cell growth, metastasis, and angiogenesis. This anti-angiogenic effect starves the tumor of oxygen and nutrients, resulting in inhibited growth or regression of the tumor in sensitive cases.

Therapeutic Indications

Pazorest 200 mg is indicated for:

Advanced Renal Cell Carcinoma (RCC):

Used as first-line treatment or after cytokine therapy in adult patients with advanced kidney cancer. Pazopanib is effective in maintaining progression-free survival and controlling disease progression.

Advanced Soft Tissue Sarcoma (STS):
Used in adults with a range of soft tissue sarcomas after chemotherapy. It must not be used in adipocytic STS or GISTs.

Dosage and Administration

The recommended standard dose of Pazopanib in adults is 800 mg per day, orally with no food (at least 1 hour prior to or 2 hours after meals). But based on patient tolerance, liver function, and therapeutic response, physicians can modify the dose.

Pazorest 200 mg tablets may be used for the purpose of administering flexible dosing—usually as part of a regimen to achieve the total daily dose of 800 mg (i.e., four 200 mg tablets). The tablets should be swallowed whole with water and not be crushed or chewed since this can lessen absorption and lead to side effects.

Pharmacokinetics

After oral administration, Pazopanib’s peak plasma concentration is between 2 and 4 hours. Pazopanib is predominantly protein-bound and is metabolized in the liver predominantly by the CYP3A4 enzyme system. Its mean half-life is approximately 30 hours, making it amenable to once-daily dosing. Pazopanib is mostly excreted in the feces with minimal renal excretion.

Contraindications

Pazorest 200 mg is contraindicated in patients who:

Have known hypersensitivity to Pazopanib or any of the excipients present in the drug

Have severe hepatic impairment

Uncontrolled hypertension

History of prolongation of QT or cardiac arrhythmias (precaution is advisable)

Warnings and Precautions

Liver Toxicity: Regular monitoring of liver function tests (ALT, AST, bilirubin) is necessary.

Hypertension: Pazopanib can be accompanied by hypertension, which must be controlled before and during treatment.

Thrombotic Events: Risk of venous and arterial thromboembolism may increase.

Wound Healing Complications: Discontinue therapy before surgery major and restart only after healing has occurred.

Proteinuria: Monitoring of urine protein is advisable.

Gastrointestinal Perforation: Rare but fatal complication.

Adverse Effects

The most frequent side effects are:

Diarrhea

Fatigue

Nausea and vomiting

Hypertension

Hair color alteration (lightening or depigmentation)

Loss of appetite

Weight loss

Hyperlipidemia (increased liver enzymes)

Hypothyroidism

Severe but less common side effects include hepatic failure, cardiac failure, hemorrhage, and reversible posterior leukoencephalopathy syndrome (RPLS).

Drug Interactions

Metabolism by CYP3A4 renders Pazopanib interactive with several drugs.

CYP3A4 inhibitors (such as ketoconazole, clarithromycin) may increase Pazopanib levels.

CYP3A4 inducers (such as rifampin, carbamazepine) may reduce its effectiveness.

Antacids and proton pump inhibitors can decrease drug absorption by altering stomach acidity.

Always inform the treating doctor of all the concomitant medications, including herbal and non-prescription drugs.

Storage and Handling

Store Pazorest 200 mg tablets away from room temperature (less than 30°C), light, and humidity. Store out of reach of children and animals. Do not store past the expiration date on the package.

Conclusion

Pazorest 200 mg (Pazopanib) is an innovative target cancer therapy in the form of advanced renal cell carcinoma and soft tissue sarcomas. Through selective inhibition of multiple tyrosine kinases responsible for tumor growth and angiogenesis, it offers patients a non-chemotherapy oral regimen to slow the pace of disease progression and improve quality of life. Yet, due to its potential for serious adverse effects, Pazorest should always be give under strict medical supervision with constant monitoring and proper dose adjustment to further enhance its safety and effectiveness.